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Difference in coagulation markers in acute and  
one year post acute ischemic stroke
Abstract
Background and purpose: Shifts of the balance between coagulation 
and fibrinolysis play a crucial role in pathogenesis of cerebral ischemia. 
However, its relevance to post-acute disease period requires further elucida-
tion. This study aimed to characterize whether hypercoagulation markers 
differ for patients in acute and the same patients in the post acute phase of 
ischemic stroke.
Materials and methods: Systemic generation of hemostasis markers 
was monitored and fraction composition was described during one year of 
disease development and treatment.
Results: Increased concentration of the markers of hypercoagulation in 
blood plasma of patients in acute as well as one year past acute phase ischemic 
stroke were shown. Thus, not all markers of hypercoagulation become rele-
vant to norm one year past ischemic stroke. It’s the first time characterization 
of the coagulation markers in acute and post acute period of the absolutely 
same group of patients was done. Our study demonstrates the difference in 
quantity and quality of the fractions of proteins with prothrombin origin 
and soluble fibrin monomer complexes which could be used as a potential 
target for the prevention of the stroke repetition.
Conclusions: We assume that prothrombin plays the most important 
role in the development of pathology tested; hence it may provide future 
targets for therapeutic strategies.
INTRODUCTION
The Global Burden of Disease Study estimated that almost 30% of all deaths were recorded after stroke attack (1,2). Stroke is the con-
sequence of an interruption to the blood flow to the brain. The most 
common cause of a stroke is an atherosclerosis, but it can also be caused 
by a hemorrhage (3,4). Thus, we can conclude that stroke is a widespread 
disease with high mortality and handicap among survivors (5). More-
over, post stroke disability has been the subject of discussion in the lit-
erature (6 ). The fact about involving of blood coagulation factors in the 
initiation of vascular complications is commonly known (7). The mon-
itoring of the hemostasis system is the basic approach for the clinic of 
cardiovascular diseases, including prevention, acute phase, the process 
of treatment and post disease period (8-10). Hemostasis factors act as 
coagulation triggers of cerebrovascular events. Numerous epidemiological 
studies confirmed the connection between certain factors of blood 
clotting and the risk of arterial thrombosis. Today fibrinogen is 
considered as a marker of vascular complications in patients with 
atherosclerosis (11-13). It was noted that the risk of cardiovascular events 
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is more related to the higher concentration of the fibrino-
gen than to the higher level of cholesterol (14). Fibrinogen 
level reflects the risk of a stroke (16 ). But some researchers 
have provided controversial evidence regarding the asso-
ciation between level of plasma fibrinogen and stroke risk 
(15), especially in the presence of a thickening of the inner 
and middle walls of the carotid arteries (17). In this 
framework, additional characterization of fibrinogen is 
necessary, especially in stroke condition. It is known that 
the main biological function of fibrinogen is an ability to 
convert into an active form of fibrin under the thrombin 
impact followed by avtivation of prothrombin – an origin 
of thrombin. A number of macromolecular derivatives of 
fibrinogen and soluble fibrin in high concentration exist 
in the blood plasma during the hemostasis disorders. 
These derivatives are soluble fibrin monomer complexes 
(SFMC) with the products of the cleavage of fibrinogen/
fibrin, which is not transformed into fibrin under the 
thrombin action (18,19). Thus, during the conversion of 
fibrinogen to fibrin, thrombin mediates the cleavage of a 
pair of fibrinopeptide A peptides and produces fibrin 
monomer, which rapidly polymerizes to form insoluble 
fibrin clots. Fibrin monomer molecules can circulate in 
blood plasma and form soluble complexes with fibrinogen 
molecules in the presence of a sufficient concentration of 
the latter and a variable amount of cross-linking induced 
dye FIIIa (22,23). Plasmas degradation of cross-linked 
fibrin forms a heterogeneous group of degradation prod-
ucts, reactive in assays for D-dimmer (26 ). Elevated levels 
of these complexes formed in the activated state of blood 
coagulation accompanied by the deep vein thrombosis 
syndrome, disseminated intravascular coagulation, ab-
dominal aortic aneurysm, pneumonia associated with 
systemic inflammatory response syndrome and coagu-
lopathy, tumor growth, sickle cell anemia (20,21,25). 
Numerous results indicated that fibrin-related products 
appear to be a useful diagnostic molecular marker to assess 
the activity of the coagulation system (21) and showed a 
distinct entity reflecting thrombin activity in patients 
with a variety of diseases in early stage (23-25). According 
to the lot of references, the diagnostic performance of 
measurement of the elevated level of D-dimer and SFM 
complexes is comparable, though the last one might be 
more sensitive and more specific for the diagnosis without 
a high negative predictive value (26 ). Thus, SFC is a more 
accurate and primary indicator than D-dimmer in dis-
tinguishing patients with coagulation disorders (27,28). 
Serial monitoring of SFMC levels in blood plasma may 
be a value in evaluating the response to therapy and pos-
sibly in identifying at-risk patients (26,28).
Given the above, detailed and thorough investigation 
of the indicator of early thrombogenic conditions such as 
SFMC as well as a pool of prothrombin origin molecules 
peptide pool formed in the bloodstream after suffering a 
stroke, has utmost importance. As we are interested in the 
timing of disease recurrence, it makes sense to pay atten-
tion to the difference of current parameters in acute stroke 
patients and one year past acute phase stroke patients. It 
was basis a foundation and purpose of the current work.
MATERIALS AND METHODS
Ethics statement. The study protocol was approved 
by the committee from ESC „Institute of biology and 
medicine”, Ukraine, and conforms to the principles out-
lined in the Declaration of Helsinki. All donors and pa-
tients or their relatives had been warned about the con-
duct of clinical research. Written, informed consent was 
obtained from all patients.
Groups characterization. Blood plasma samples were 
taken from 35 healthy donors as well as 66 patients with 
atherothrombotic ischemic stroke (AIS) and 56 patients 
with cardioembolic ischemic stroke (CIS) during the 
acute phase of disease; 56 patients with AIS and 56 pa-
tients with CIS one year past acute phase. Patients were 
hospitalized in the neurological department of the Hos-
pital №4 (Kyiv, Ukraine). The diagnosis of ischemic 
stroke was confirmed through computed tomography or 
magnetic resonance imaging. The severity of neurological 
disorders in patients was assessed on the basis of the 
National Institute of Health Stroke Scale (NIHSS) scale, 
USA. According to the severity of the initial neurological 
deficiency, the patients were divided as follows: with 
neurological disorders of a mild degree – 18.9 % of 
patients (6.7 ± 1.1 points), with an average severity of 
neurological disorders – 51.9 % of patients (10.9 ± 0.8 
points), for 21.4 % of patients severe neurological disorders 
(13.9 ± 0.9 points) were recorded, and for 7.8 % of patients 
had too severe neurological deficits (17.1 ± 0.6 points). On 
the first day of admission to the hospital, all patients re-
ceived aspirin 325 mg orally, then 100 mg aspirin daily. 
Starting from the second day of hospital stay, patients 
were receiving low molecular weight heparin in prophy-
lactic dose.
Sample collection. Fasting blood samples were col-
lected from the cubital vein of all patients on the 1st day 
of hospitalization as well as from the same group of pa-
tients one year past acute phase of the disease. Thus we 
obtained two blood samples from each patient: first in the 
period of stroke aggravation and second – one year after 
treatment. Blood was collected into 3.8% sodium citrate 
(in ration 9:1). Plasma was separated by further centrifu-
gation at 2000 g for 15 min at the room temperature and 
stored at −20° C until experiments were performed. Col-
lective pool of blood plasma of each tested pathologies as 
well as for healthy donors was prepared for further ex-
periment.
Obtaining of the fraction of the vitamin K-depen-
dent proteins. 1 ml of blood plasma of each tested sub-
types of ischemic stroke was continually inc meal mixed 
with 30 mg of BaSO4 per 1 hour on the ice. The mixture 
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was centrifuged at 2000g for 15 min. Elution of vitamin 
K-dependent fractions from the precipitate was done by 
adding of 50 mM Tris-HCl buffer, pH 7.4, containing 
200 mM NaCl and 20 mM EDTA (30). The proteins 
with prothrombin origin content at the separated vitamin 
K-dependent fractions was measured by standard enzyme 
linked by immunosorbent assay (ELISA) techniques (31, 
32) The ELISA plates were coated overnight at 4°C with 
vitamin K-dependent fractions samples previously diluted 
10-fold with 50 mM Tris-HCl containing 130 mM NaCl, 
pH 7.4. After being washed, plates were blocked with 5% 
nonfat dry milk in 50 mM Tris-HCl containing 130 mM 
NaCl, pH 7.4 for 1 h at 37ºC and washed again. Then the 
plates were incubated for 1 h at 37ºC with rabbit poly-
clonal antibodies (Shijin International, Mongolia) to pro-
thrombin. Plates were washed and incubated for 1 h at 
37ºC with corresponding secondary antibodies (Sigma, 
USA) which were conjugated to horseradish peroxidase. 
After washing, substrate (o-phenylenediamine and hydro-
gen peroxide) was added. Plates were read at 492 nm by 
a microplate spectrophotometer (Quant TM, BioTek In-
struments, Inc, USA).
Obtaining of the fraction of the soluble fibrin 
monomer complex (SFMC). SFMC were collected from 
the 1 ml of blood plasma of each tested subtypes of isch-
emic stroke by incubation with 0.78% o-phenanthroline 
per 5 min. The mixture was centrifuged at 2000g for 15 
min at the room temperature. The precipitate was washed 
three times by the addition of 0,9% NaCI in a volume 
equal to the initial volume of plasma. The concentration 
of SFMC was measured through the time record from the 
moment of the addition of the reagent until the first of 
the cereals (grains) of fibrin. Accounting was performed 
up to 150 sec. The test was considered positive after ma-
terialization of clearly visible in transmitted light flakes or 
grains, which were noted for the first 150 seconds. The 
time of the flakes or grain appearance was noted in sec-
onds and concentration was calculated according the 
calibration chart (33).
Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis analysis (SDS-PAGE). Aliquots in volume 
50 mkl of each tested fraction of vitamin K-dependent 
plasma protein as well as soluble fibrin monomer com-
plexes were diluted 10 times by SDS-PAGE sample buffer 
and applied on 8% polyacrylamide gel according to 
Laemmli (34,35). Gels were stained with 0.125% solution 
of Coomassie Brilliant Blue G-250 in 25% isopropanol 
and 10% acetic acid.
Western Blot analysis. Following electrophoresis, 10 
times diluted aliquots were transferred into Amersham 
Hybond-C Membrane under standard conditions. West-
ern blot detection was performed using primary poly-
clonal anti-a-FDP antibody (for SFMC fractions ali-
quots) or polyclonal antibodies to prothrombin (for 
vitamin K-dependent fractions aliquots) both in the ra-
tion 1:2000 (Shijin International, Mongolia). Correspond-
ing secondary antibodies (Sigma, USA) horseradish per-
oxidase-conjugated antibody in ratio 1 : 1500 were 
de tected by 3.3’-diaminobenzidine (DAB) substrate 5 
mg/ml with 30% H2O2.
Chromatographic separation. Size-exclusion chroma-
tography of each tested fractions of vitamin K-dependent 
plasma protein as well as soluble fibrin monomer com-
plexes were performed. Aliquots in volume 1 ml was ap-
plied on Healthcare Life Sciences (HiLoad 16/60 Super-
dex 200 pg) column in 50 mM Tris-HCl, pH 7.4 with 
the addition of 130 mM NaCl. The column volume was 
equal 120 ml. The stable speed was 1 ml/min (36,37). A 
standard ladder with known molecular weight was ap-
plied to the column for calibration.
Statistical processing of the results was performed 
using software Statistica 7 and Origin 9.1. Value changes 
were considered as significant at P < 0.05. Analysis of 
electrophoregrams was performed by the scanning of the 
computer program TotalLab 2.01.
RESULTS
Proteins with prothrombin origin fractions as well as 
SFMC fraction were obtained from each tested group: 
healthy donors, patients with acute AIS, acute CIS and 
the same group of patients one year past AIS or CIS. The 
concentration of both coagulation markers was deter-
mined. We have determined that the concentration of 
SFMC during the acute atherothrombotic ischemic 
stroke was 33.4±15.2 mkg/ml, while maximum concen-
tration (46.2±4.1 mkg/ml) was determined in 27% of 
patients. For patients with cardioembolic ischemic stroke 
SFMC was 37.0±11.8 mkg/ml and 25% of patients in this 
group had elevated level of SFMC (47.6±5.3 mkg/ml). 
One year past average SFMC concentration for patients 
with AIS was 8.1±2.6 mkg/ml and for patients with CIS 
14.8±3.4 mkg/ml. It is important to underline that such 
concentrations for post stroke fractions were average for 
all tested past stroke patients without deviations in groups 
(Table 1).
As known, one of the recently discovered and insuffi-
ciently studied risk factors for ischemic stroke develop-
ment is a production of antibodies directed toward a 
phospholipid binding protein, in particular to prothrom-
bin. The ability of these antibodies to reduce the func-
tional activity of the target proteins promotes disturbance 
of pro-and anticoagulant balance. To clarify the charac-
teristics of the blood coagulation system, we measured the 
total pool of molecules of prothrombin origin. Applying 
of polyclonal antibodies allowed us to estimate the con-
tent of not only prothrombin, but also molecules contain-
ing epitopes of prothrombin origin, in particular, inter-
mediates of prothrombin activation, thrombin molecules 
and their complexes. And so we have determined that the 
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increase of a pool of prothrombin derivatives occurs in 
both types of stroke.
Thus, for atherothrombotic ischemic stroke the concen-
tration of the peptides with prothrombin origin was 
0.84±0.27 u/ml, while maximum concentration (1.036±0.1 
u/ml) was detected in 12% of patients. For patients with 
cardioembolic ischemic stroke concentration was 0.73±0.1 
u/ml and 21% of patients in this group had an elevated 
level of peptides with prothrombin origin (1.02±0.1 u/
ml). One year post stroke the differentiation inside groups 
of stroke patients was absent. And for patients with AIS 
the protein with prothrombin origin fraction concentra-
tion was in average 0.47±0.08 u/ml and for CIS was 
0.43±0.08 u/ml. (Table 1).
Concentrations of both the protein with prothrombin 
origin as well as SFMC become close to norm one year 
after ischemic stroke.
At the next step, 8% SDS-PAGE was performed 
(Fig. 1).
Results showed the presence of vitamin K-dependent 
proteins in the blood plasma of both subtypes ischemic 
stroke in the range from 40 to 250 kDa. SDS-PAGE of 
SFMK showed the presence of protein in the range from 
20 to over 330 kDa. Fractions with a molecular weight 
over 330 kDa correspond to SFMC. Additional proteins 
are the consequence of the cleavage of fibrin/fibrinogen 
by plasmin in the blood plasma.
Western blot analysis showed that the presented mol-
ecules with prothrombin origin in all tested fractions in 
the range from 30 to 250 kDa were corresponded to 
prothrombin its degraded forms and complexes (Fig. 1, 
Table 2).
Protein with Mr 70±5 kDa belongs to prothrombin as 
well as 37 kDa to thrombin were detected in each tested 
Table 2. Western blot analysis of content of the proteins with pro-





















240 + + + + +
220 + + + + +
200 + + + + +
160 + + + + +
130 + + + + +
118 + + + + +
84 + + + + +
75 + + + + +
50 + + + + +
40 + + + + +
35 + + + + +
Table 1. Characterization of the proteins with prothrombin origin 
and soluble fibrin monomer complexes concentration in blood 
plasma of the patient with stroke.





Healthy donors 0.47 2.0




Year past 0.47±0.08 8.1±2.6*




Year past 0.43±0.08 14.8±3.4*
* – Statistically significant changes in comparison with the healthy 
donors, p<0.05
Parameters are expressed as means±SD
Figure 1. Analysis of the coagulation markers: A. Soluble fibrin 
monomer complexes fraction; B. Proteins with prothrombin origin 
fraction (A/B1. SDS PAGE image; A/B2. Western Blot image), 
obtained from blood plasma of: 1. Healthy donors; 2. Patients in 
acute atherothrombotic ischemic stroke; 3. Patients in acute cardio-
embolic ischemic stroke; 4. Patients year past acute phase of athero-
thrombotic ischemic stroke; 5. Patients year past acute phase of 
cardioembolic ischemic stroke; 6. MW standards The Thermo Sci-
entific PageRule Prestained Protein Ladder, from 10 to 170 kDa.
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fractions. Mostly, detected proteins were identified in 
both peptide pool fractions for CIS and AIS patients as 
well as healthy donors’ fractions.
According to the western blot proteins with Mr from 
100 kDa to over 330 kDa in the healthy donors SFMC 
sample were detected (Fig. 1, Table 3).
The similar contents were identified in the acute AIS 
fraction. Acute CIS as well as both year past stroke frac-
tion was characterized by the presence of proteins and 
their fragments or complexes with Mr starts from 10 to 
over 330 kDa.
At the next step, the size-exclusion chromatography 
was performed to characterize the content of tested frac-
tions of vitamin K-dependent plasma proteins as well as 
SFMC fractions. It was shown that development of isch-
emic stroke accompanied by the formation of SFMC in 
the bloodstream could take part in disease complication 
(Fig. 2).
The results suggest the presence of proteins with Mr 
from 45 up to 330 kDa. The content of SFMC was simi-
lar for all stroke fractions with some exceptions. The dif-
ference between results of separation of stroke factions 
and fractions obtained from healthy donors was obvious. 
Mostly the protein content of the SFMC fraction is simi-
lar for stroke and healthy fractions. But mount of the 
proteins as mean peaks high is different. (Table 4).
The presence of fragments with a molecular weight 
about 330 kDa was characteristic for all tested groups. Its 
elution volume was equal 0.15±0.02 pc. of the column 
volume (1 pc = 1 column volume, in our case it is equal 
to 120 ml).
The same situation was inherent for complexes with 
Mr from 280 to 250 kDa. These fractions were present in 
the healthy donor’s fraction too, but in smaller amounts. 
In fact, the first three peaks of chromatogram of SFMC 
are common for all tested fractions and were verified only 
in their height.
Both acute and one year past AIS SFMC fractions in-
cluded the complexes with Mr 215 kDa and 180 kDa. The 
Table 3. Western blot analysis of content of soluble fibrin monomer 





















>330 + + + + +
260 + + + + +
250 + + + + +
220 + + + + +
195 + + + + +
160 + + + + +
130 + + + + +
100 + + + + +
80 + + + + +
60 + + + + +
45 - + + + +
35 - + + + +
25 - - - + +
10 - - - + +
Figure 2. Size-exclusion chromatography separation of: A – Soluble fibrin monomer complexes fraction; B – Proteins with prothrombin origin 
fraction; obtained from the blood plasma of: 1. Patients year past acute phase of atherothrombotic ischemic stroke; 2.Patients in acute athero-
thrombotic ischemic stroke; 4. Healthy donors; 4. Patients year past acute phase of cardioembolic ischemic stroke; 5. Patients with acute cardio-
embolic ischemic stroke.
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elution volumes of these proteins were 0.35 and 0.45 pc. 
of the column volume. The height was 1.75 and 1.73 s.u 
for acute, and 0.7 s.u. for one year past AIS. However, CIS 
unlike AIS had the same peak just for one year past of 
disease.
Accordingly, the most widely represented variations 
peak for AIS. Even a year after stroke soluble fibrin mono-
mer complex content was higher compared to the healthy 
donors’ index. Healthy donors also had some of these 
complexes, but in trace amounts. For acute CIS situation 
was similar as for AIS, but past one year it got closer to 
healthy donors.
Results of chromatographic separation of vitamin K-
dependent fractions obtained from the patients with isch-
emic stroke in acute and post acute phases suggests the 
presence of proteins with Mr from 70 to higher 200 kDa 
(Fig. 2B, Table 5). Most all peaks were presented in each 
tested fractions. Just the high of peaks had been different 
for each tested fractions.
Thus the proteins with Mr >200 kDa as well as 150 
kDa and 120 kDa were discovered in each fraction in-
cluded healthy donors’ fraction but in different 
amounts. The highest peak was observed in both AIS 
fraction in acute and one year past acute ischemic stroke 
patients. Their heights were equal 7.4 and 8.1 s.u. ac-
cordingly. The height of CIS and healthy donors’ frac-
tions was 3.6±0.2 s.u. The volume of elution of SFMC 
was >0.1 pc. of column volume. We received SFMC in 
the same peaks with protein with Mr 150 kDa. The area 
under this peak was bigger and was equal to 0.45±0.2 
s.u. in average. Elution volume of protein with Mr 150 
kDa was 0.11 pc. And for protein with Mr 120 kDa was 
0.13 p c. of the column volume. Interesting that protein 
with Mr 75 kDa was found just in the one year past 
CIS fraction. The elution volume for a 75 kDa protein 
from post acute CIS fraction was 0.26 kDa. Protein 
with Mr 70 kDa was fined in each tested fractions too. 
The elution volume of this peak was 0.26±0.2 pc. Im-
portant to say that the highest peak of protein 70 kDa 
Table 4. Analysis of size-exclusion chromatographic separation of the soluble fibrin monomer complex fraction from blood plasma of ischemic 
stroke patients.
Soluble fibrin monomer complex  
separated from the blood plasma of










Healthy donors 0.18918 1 0.15 >300 10.10
0.02729 2 0.23 280 0.90
0.06337 3 0.24 260 0.80
0.17065 4 0.51 100-45 4.05
Patients with acute atherothrombotic 
ischemic stroke
0.29305 1 0.17 330-300 15.50
0.13172 2 0.23 265-280 12.53
0.09558 3 0.24 250 5.70
0.07276 4 0.35 215 1.75
0.0718 5 0.45 180 1.73
0.51635 6 0.51 100-45 13.00
Patients with acute cardioembolic 
ischemic stroke
0.14977 1 0.17 300 13.05
0.01753 2 0.23 280 0.90
0.05426 3 0.24 260 0.80
0.09486 4 0.51 100-45 1.01
Patients with past one year  
atherothrombotic ischemic stroke
0.1618 1 0.17 300 13.05
0.05549 2 0.23 265-280 5.40
0.03587 3 0.24 250 2.50
0.02209 4 0.35 215 0.70
0.02293 5 0.45 180 0.70
0.0767 6 0.51 100-45 2.42
Patients with past one year  
cardioembolic ischemic stroke
0.06036 1 0.17 300 2.80
0.08166 2 0.23 265-280 9.50
0.0286 3 0.24 260 2.10
0.01414 4 0.35 215 0.60
0.03892 5 0.51 100-45 0.70
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was observed in healthy donors’ fraction – 3.0 s. u. For 
stroke fraction, the height of this peak was in average 
2.2±0.2 s.u.
DISCUSSION
Hemostasis is one of the most complex physiological 
self-defense systems which ensure blood fluidity, the 
maintenance of the rheological properties in the physio-
logical ranges and rapidly induces hemostatic plug forma-
tion in order to stop or limit bleeding (38). Hemostatic 
imbalance, due to the influence of both internal and ex-
ternal factors, increases the risk of bleeding or thrombosis. 
The study of the functional state of prothrombin causes 
significant interest because of prothrombin’s involvement 
in not only the realization of several physiological reac-
tions, but also because of its interfering in major physio-
pathological processes, in particular, the regulation of 
vascular tone, wounds healing, immune response imple-
mentation, development of inflammation, tumors, Al-
zheimer’s disease, atherogenesis and others (39-41). Sol-
uble fibrin monomer complexes (SFMC) are the earliest 
marker of thrombophilia that represents the complexes of 
monomeric fibrin with fibrinogen or their products of 
degradation (FDP). Detection of the SFMC, formed due 
to the activation of blood clotting by thrombin, reveals a 
pathological process in the early, preclinical stages (42). 
SFMC levels are not directly affected by therapy with 
heparin or thrombolytic agents and may contribute to an 
accurate diagnosis of thrombotic events. The increased 
soluble fibrin monomer is typical for the development of 
disseminated intravascular coagulation, autoimmune dis-
eases and thrombophilia (43).
Extrinsic pathway of the clotting process is initiated 
by tissue factor which forms a complex with plasma pro-
tein activated vitamin K-dependent factor VII with Mr 
50 kDa. Than activation of another K-dependent factor 
– factor X take place, which activates the main protein of 
the blood coagulation thrombin from the two-chain gly-
coprotein prothrombin with Mr 72 kDa. One of the 
regulative anticoagulant here is protein S, a single-chain 
K-dependent glycoprotein with a Mr 84 kDa, which of 
free form functions as a cofactor to Protein C. The protein 
with corresponded molecular weight were detected in the 
fraction of vitamin K-dependent factors tested.
The evolution of our knowledge of the physiology of 
hemostasis has numerous implications for therapy. De-
fects associated with the pathways of blood coagulation 
can be assessed with specific tests. In order to estimate 
the activity of blood coagulation factors, we determined 
the concentration of tested fractions of prothrombin pool 
Table 5. Analysis of size-exclusion chromatographic separation of the vitamin K-dependent plasma proteins fraction from blood plasma of ischemic 
stroke patients.
Proteins with prothrombin origin 
separated from the blood plasma of










Healthy donors 0.23163 1 0.11 >200 3.7
0.31798 2 0.13 120 4.0
0.03592 3 0.24 85 0.09
0.21266 4 0.29 70 3.0
Patients with acute atherothrombotic 
ischemic stroke
0.47355 1 0.11 >200 7.4
0.44534 2 0.13 120 6.0
0.0357 3 0.24 85 0.08
0.19243 4 0.29 70 2.3
Patients with acute cardioembolic 
ischemic stroke
0.29942 1 0.11 >200 3.5
0.32758 2 0.13 120 4.9
0.02934 3 0.24 85 0.09
0.18702 4 0.29 70 2.3
Patients with past one year  
atherothrombotic ischemic stroke
0.54775 1 0.11 >200 8.1
0.4079 2 0.13 120 5.2
0.03625 3 0.24 85 0.09
0.18709 4 0.26 70 2.2
Patients with past one year  
cardioembolic ischemic stroke
0.24781 1 0.11 >200 3.8
0.25453 2 0.13 120 3.1
0.03837 3 0.24 85 0.1
0.01969 4 0.26 75 0.1
0.18856 5 0.29 70 2.1
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as well as SFMC and characterized it component com-
position.
It is well known that blood coagulation is a complex 
reaction network that functions to form a fibrin clot that 
covers the damaged vessel wall and prevents blood loss 
(44). It should be noted that the generation of thrombin 
can be confirmed by accumulation in plasma of N- ter-
minal part of the prothrombin molecule fragment F1+2 
(47), the molecular weight of that is about 40 kDa. Phys-
iological activation of prothrombin, except the formation 
of thrombin, can be accompanied by accumulation of a 
number of intermediates, some of that possess enzymatic 
activity (meizothrombin, meizothrombin 1) and the oth-
er one belongs to the functionally inactive derivatives 
(prethrombin 1, 2, fragments 1, 2, 1+2). Protein fractions 
with a molecular weight about 50 and 37 kDa may consist 
of prethrombin 1 and 2, which is agreed with literature, 
according to that, their appearance in the bloodstream 
serves as an early marker of intravascular coagulation (48). 
Meizothrombin (about 70 kDa) is one of the transient 
intermediates that are produced during the conversion of 
prothrombin to thrombin in systems composed of factor 
Xa and factor Va that are quantitatively assembled on an 
anionic phospholipid surface. The presence in blotogram 
of the proteins with molecular weights about 118, 136, 
170 kDa and others could be result of a formation of pro-
thrombin and its derivative complexes with proteins at the 
term of ischemic stroke progression. For example, the ap-
pearance in the bloodstream of thrombin-antithrombin 
III complexes (molecular weight about 118 kDa) is re-
garded as one of the diagnostic criteria for thrombosis 
development. On the other hand, Mr 118 kDa could be-
long to high molecular weight kininogen which is a cir-
culating plasma protein. which participates in the initia-
tion of blood coagulation, and in the generation of the 
vasodilator bradykinin via the Kallikrein-kinin system. It 
was reported that prothrombin is able to replace high mo-
lecular weight kininogen as a cofactor for the specific 
binding of factor XI to the platelet (44). Other literature 
data provided the evidence about formations of the stable 
complexes of thrombin with sodium dodecyl sulfate in the 
range of 77 and >450 kDa with proteins secreted by acti-
vated platelets which had no catalytic activity (46 ).
As known thrombin initially cleaves fibrinopeptide A 
(FPA) and then fibrinopeptide B (FPB) from the A and B 
chains of fibrinogen, as a result the exposure of new N-
termini and causing conformational changes and expo-
sure of polymerization sites take place (49). This generates 
„fibrin monomer”, a molecule with a strong tendency to 
polymerize that can be isolated and characterized in vitro 
only under stringent dissociating conditions to prevent 
polymerization. Thrombin also activates factor XIII as 
fibrin is formed, and factor XIIIa rapidly cross-links ad-
jacent g chains in fibrin polymers. Small amounts of fibrin 
monomer may not be incorporated into growing clot, but 
rather circulate in the plasma complex with fibrinogen or 
degradation products (50). The formation of g chain cross-
links in fibrin that are resistant to degradation leads to the 
formation of unique degradation products that differ 
from those of fibrinogen. Consequently, soluble products 
produced with the g chain cross-link intact, and leads to 
the formation of a large number of polymeric forms of 
defined structure or thrombin-treated fibrin fragments X, 
Y and E, or the fibrinogen-derived fragments X, Y, D and 
E, or the D-dimer. Under physiological conditions, D-
dimer is smaller and is in no covalent complex with the E 
domain of a fibrin unit from an adjacent strand to form 
the DD(E) complex. If proteolysis is stopped in vitro be-
fore degradation goes to completion, a heterogeneous 
group of larger products can be identified. Assays for 
SFMC as well as fibrin degradation products are impor-
tant markers for the diagnosis and monitoring of hyper-
coagulable states and disseminated intravascular coagula-
tion. A lot of authors had discussed the prevalence of the 
diagnostic potential between SFMC and D-dimer. And 
most of them inclined to SFMC (27, 26 ).
Fibrinogen is a 330-kDa soluble plasma protein con-
sisting of three pairs of disulfide-bonded a-, b-, and g-
chains were noted in each tested fractions. Fragmentation 
of fibrinogen occurs upon cleavages within the a-chain 
to release the aC fragments, thereby producing fragment 
X (260 kDa). Further cleavage of fragment X in the a-, 
b-, and g-chains between the two disulfide rings in one 
half of the molecule produces fragment Y (160 kDa) and 
fragment D (100 kDa). Thus thrombin-treated fibrin 
fragments were noticed in each tested fractions. Further 
cleavage of fragment Y produces a second fragment D and 
fragment E (60 kDa) which were not noticed in healthy 
donors and acute AIC fractions.
CONCLUSION
As known the highest level of repetition belongs to the 
stroke. The appearance in the bloodstream after a stroke 
attack of some pathological protein or peptide could be a 
reason of such repetition. The detailed and advanced 
characterization of the proteins, especially markers of hy-
percoagulation and fibrinolysis, in the bloodstream of 
patients with cardiovascular disorders will help to find the 
answer to the question about stroke repetition, pathogen-
esis and treatment.
This fact is an indicator of the normal activation of 
coagulation of the patients with chronic ischemic stroke, 
which is a flagman of balance between hemostasis disor-
ders and rehabilitation.
We can assume that prothrombin plays an important 
role in the pathological process of the ischemic stroke 
development.
It was proved that o-phenanthroline method of solu-
ble fibrin monomer complexes separation is accompa-
nied by the additional precipitation of fibrinogen and 
fibrin fragments.
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The presence of fibrin and fibrinogen degradation 
products in the acute CIS fraction and the absence of 
these fragments in acute AIS fractions showed the shift 
in time of the fibrinolysis process for AIS in contrast to 
the CIS.
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